AXGT

Axovant Gene Therapies (AXGT)

Axovant Gene Therapies Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AXGT

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/04/26	05 : 05	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(g) (15-12g)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/04/18	05 : 17	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/04/18	05 : 14	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/04/12	21 : 52	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/04/07	05 : 08	Edgar (US Regulatory)	Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/04/07	05 : 07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/03/17	19 : 03	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/03/16	05 : 26	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/02/22	06 : 06	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (definitive) (defm14a)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/02/14	21 : 04	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/02/14	21 : 02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/02/14	20 : 47	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/02/13	22 : 53	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/02/11	06 : 01	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2023/02/09	20 : 01	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (preliminary) (prem14a)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/12/15	06 : 11	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/12/15	06 : 05	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/11/10	21 : 04	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/11/10	21 : 03	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/09/15	05 : 09	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/08/11	20 : 04	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/06/14	20 : 02	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/02/15	03 : 58	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/02/11	21 : 03	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/02/11	21 : 01	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/02/11	07 : 08	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/02/09	21 : 01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2022/01/26	06 : 51	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2021/12/10	08 : 32	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:AXGT	Axovant Gene Therapies Ltd
2021/12/10	08 : 31	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:AXGT	Axovant Gene Therapies Ltd